<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356170</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC 2019-01</org_study_id>
    <nct_id>NCT04356170</nct_id>
  </id_info>
  <brief_title>Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma</brief_title>
  <acronym>TPFmORL</acronym>
  <official_title>A Phase II Randomized Trial, Non Comparative, Evaluating Chemotherapy Associated Cisplatin, 5-fluorouracil and Docetaxel at Adapted Doses in Patients With Locally Advanced Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacity of the combination of
      cisplatin-5-FU and docetaxel in adapted doses in term of response to treatment without
      toxicity

      .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After explaining the treatment modalities, having read and explained the information letter
      to them, patients who have signed the consent to participate in the trial and who meet the
      inclusion criteria will be enrolled and randomized in the trial .
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacity of combination of TPFm</measure>
    <time_frame>8 weeks after the end of treatment</time_frame>
    <description>Success rate of patients at 8 weeks</description>
  </primary_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 months after the end of treatment</time_frame>
    <description>The time from date of randomization to date of death due to any cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 months after the end of treatment</time_frame>
    <description>The time from date randomization to date of first evidence of progression</description>
  </other_outcome>
  <other_outcome>
    <measure>incidence of local and/or locorégional failure</measure>
    <time_frame>3 months after the end of treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laryngeal preservation</measure>
    <time_frame>3 months after the end of treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>incidence of distant metastatic failure</measure>
    <time_frame>3 months after the end of treatment</time_frame>
    <description>The time from the date of randomization and the date of first evidence of metastatic progression, or the date of death, whatever the cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Toxicities of complementary treatment to induction tretatment</measure>
    <time_frame>3 months after the end of treatment</time_frame>
    <description>Rate of patients who received the whole of complementary treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>QLQ-C30 questionnaires</measure>
    <time_frame>8 weeks, 6 months (3 months after the end of treatment) and 24 months after the end of treatment</time_frame>
    <description>These questionnaires assess the impact of the desease and treatment on tthe patient's life</description>
  </other_outcome>
  <other_outcome>
    <measure>QLQ-H&amp;N35 questionnaires</measure>
    <time_frame>8 weeks, 6 months (3 months after the end of treatment) and 24 months after the end of treatment</time_frame>
    <description>These questionnaires assess the impact of the desease and treatment on tthe patient's life</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Cancer of Head and Neck</condition>
  <arm_group>
    <arm_group_label>TPF (docetaxel, cisplatine, 5-FU)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel, cisplatine, 5-FU administered, every 3 weeks for a total of 3 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPFm (docetaxel, cisplatine, 5-FU) modifié</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel, cisplatine, 5-FU administered, every 2 weeks for a total of 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour</description>
    <arm_group_label>TPF (docetaxel, cisplatine, 5-FU)</arm_group_label>
    <arm_group_label>TPFm (docetaxel, cisplatine, 5-FU) modifié</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>cisplatine 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour</description>
    <arm_group_label>TPF (docetaxel, cisplatine, 5-FU)</arm_group_label>
    <arm_group_label>TPFm (docetaxel, cisplatine, 5-FU) modifié</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoro Uracil</intervention_name>
    <description>750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)</description>
    <arm_group_label>TPF (docetaxel, cisplatine, 5-FU)</arm_group_label>
    <arm_group_label>TPFm (docetaxel, cisplatine, 5-FU) modifié</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven squamous cell carcinoma of the head and neck from one or more of
             the following primary sites: oral cavity, oropharynx, hypopharynx or larynx,
             lymphadenopathy without front door

          2. Inoperable tumor or tumor whose surgery would be multilating.

             The non-operability criteria are:

               -  Technically impossible resection: fixation / invasion of the tumor at the base of
                  the skull or at the cervical vertebrae, nasopharynx involved, lymph nodes

               -  Medical selection based on low surgical curability. This category includes all
                  T3-T4 and all N2-N3 (AJCC 8th edition, June 2018)

               -  Medical selection based on an organ preservation strategy

          3. Patient not previously treated for ORL cancer

          4. Age &gt; 18 and &lt; 75 years

          5. PS 0 or 1 according to WHO

          6. At least one lesion measurable according to the RECIST 1.1 criteria

          7. Patient who can receive TPF according to the following criteria:

               -  Adequate hematological function: neutrophils ³ 1.5 x 109 / l, platelets ³ 100 x
                  109 / l, hemoglobin ³ 10 g / dl (or 6.2 mmol / l)

               -  Adequate renal function: calculated creatinine clearance (Cockroft &amp; Gault) or
                  measured ³ 60 ml / min.

               -  Adequate liver function: normal total bilirubin; ASAT and ALAT less than or equal
                  to 1.5 ´ LNS; PAL less than or equal to 2.5 X LNS

               -  Grade &lt;2 peripheral neuropathy according to NCI CTCAE v5.0

               -  No clinical impairment of hearing function

               -  For patients aged 71 to 74, PS at 0 and considered non-geriatrically fragile (G8
                  questionnaire and multidimensional assessments proposed by the GERICO group (ADL,
                  MMSE, GDS scale, nutrition, motor skills and balance, geographic and personal
                  situation and assessments) thymic))

          8. Estimated life expectancy greater than or equal to 3 months

          9. Weight loss of less than 10% during the 3 months before randomization

         10. Patient understanding French and able to complete quality of life questionnaires

         11. Patient having given written consent before any specific protocol procedure

         12. Affiliation to a social security scheme or beneficiary of such a scheme

        Exclusion Criteria:

          1. Trans-glottic T3 with massive infiltration of the hemilarynx or T4 with massive
             cartilage lysis or tumor of the retro-cricoarythenoid region or of the posterior
             hypopharyngeal wall

          2. Vaccination against recent or planned yellow fever

          3. Known deficiency in dihydropyrimidine dehydrogenase (DPD) or determined by the
             determination of uricemia.

          4. History of other cancer except in situ cervical cancer or controlled basal cell
             carcinoma. Patients in remission from cancer treated more than 3 years ago are
             eligible. Patients treated by surgery alone for ORL cancer in the previous 3 years are
             eligible.

          5. Previous treatment of an ORL cancer by chemotherapy or radiotherapy Patients treated
             by surgery alone for ORL cancer in the previous 3 years are eligible).

          6. Presence of distant metastasis.

          7. Participation in a therapeutic trial in the 30 days preceding randomization

          8. Concomitant anticancer treatment

          9. Patient under chronic treatment (3 months) with corticosteroid whose daily dosage is
             20 mg / day of methylprednisolone or equivalent

         10. Other existing serious medical pathologies (non-exhaustive list):

               -  Uncontrolled cardiac pathology despite adequate treatment

               -  Myocardial infarction in the 6 months preceding randomization

               -  Neurological or psychiatric history such as dementia, convulsions

               -  Active infection

               -  Significant gastrointestinal abnormalities, including those that require
                  parenteral nutrition, active peptic ulcer, and history of surgeries affecting
                  absorption

               -  Obstructive pulmonary disease requiring hospitalization in the year preceding
                  randomization

               -  Uncontrolled type II diabetes or other corticosteroid contraindications.

               -  Moderate or severe eczema

         11. Known hypersensitivity to docetaxel, cisplatin 5FU or one of their excipients.

         12. Intended concomitant use of phenytoin, carbamazepine, barbiturates or rifampicin

         13. Presence, upon selection, of psychological, family, social or geographic factors
             likely to influence the patient's compliance with the study and monitoring protocol.

         14. Pregnant or lactating woman

         15. Patient (male or female) of reproductive age who is unable or unwilling to take
             adequate contraceptive measures during treatment and up to 6 months after the last
             treatment is administered.

         16. Persons deprived of their liberty, under guardianship or curatorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ORL cancer without front door, TPFm, inoperable tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

